These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32533817)

  • 1. Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.
    Al-Nema MY; Gaurav A
    Curr Top Med Chem; 2020; 20(26):2404-2421. PubMed ID: 32533817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychiatric aspects of phosphodiesterases: An overview.
    Murthy VS; Mangot AG
    Indian J Pharmacol; 2015; 47(6):594-9. PubMed ID: 26729948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors as potential cognition enhancing agents.
    Schmidt CJ
    Curr Top Med Chem; 2010; 10(2):222-30. PubMed ID: 20166957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting.
    Zhang HT
    IDrugs; 2010 Mar; 13(3):166-8. PubMed ID: 20191432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
    Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
    Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of phosphodiesterases in schizophrenia : therapeutic implications.
    Siuciak JA
    CNS Drugs; 2008; 22(12):983-93. PubMed ID: 18998737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
    Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
    Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
    Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
    Goff DC; Coyle JT
    Am J Psychiatry; 2001 Sep; 158(9):1367-77. PubMed ID: 11532718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction.
    Duinen MV; Reneerkens OA; Lambrecht L; Sambeth A; Rutten BP; Os JV; Blokland A; Prickaerts J
    Curr Pharm Des; 2015; 21(26):3813-28. PubMed ID: 26044976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase inhibitors for cognitive enhancement.
    Rose GM; Hopper A; De Vivo M; Tehim A
    Curr Pharm Des; 2005; 11(26):3329-34. PubMed ID: 16250839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.
    Świerczek A; Jankowska A; Chłoń-Rzepa G; Pawłowski M; Wyska E
    Curr Drug Targets; 2019; 20(16):1652-1669. PubMed ID: 31368871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing Drugs for Cognition in Schizophrenia.
    Yang YS; Marder SR; Green MF
    Clin Pharmacol Ther; 2017 Feb; 101(2):191-193. PubMed ID: 27706797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.
    Reneerkens OA; Rutten K; Steinbusch HW; Blokland A; Prickaerts J
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):419-43. PubMed ID: 18709359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents.
    Harada A; Kaushal N; Suzuki K; Nakatani A; Bobkov K; Vekich JA; Doyle JP; Kimura H
    Int J Neuropsychopharmacol; 2020 Feb; 23(2):96-107. PubMed ID: 31689714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.